Poor
Not Aligned
Patient Risk:
High
Summary
Several claims about mechanism and monitoring align with the provided label excerpts, but multiple high-safety-risk inaccuracies/unsupported details are present, including an unlabeled liver-injury incidence estimate, an unsupported symptom list, and interaction/emergency-stop guidance that is not supported by the provided prescribing information.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication that works by inhibiting the production of cholesterol in the liver.
12.1 Mechanism of Action (inhibits HMG-CoA reductase; cholesterol synthesis in the liver)
Lipitor blocks the enzyme HMG-CoA reductase.
12.1 Mechanism of Action (selective, competitive inhibitor of HMG-CoA reductase)
Lipitor reduces low-density lipoprotein (LDL) cholesterol in the blood.
12.1 Mechanism of Action (reduces LDL-C/LDL production/LDL particles)
A doctor may perform blood tests to check for liver damage in people taking Lipitor.
5.2 Liver Dysfunction (liver function tests recommended prior to and at 12 weeks following initiation and after dose increases; periodically thereafter)
Regular blood tests can help detect liver damage early while taking Lipitor.
5.2 Liver Dysfunction (timing of recommended liver function tests)
Doctors may monitor liver function regularly while patients take Lipitor.
5.2 Liver Dysfunction (periodically, e.g., semiannually thereafter)
Unsupported Statements
The text states that liver damage occurs in about 1 in 100,000 people who take Lipitor.
No incidence estimate like “1 in 100,000” is present in the provided label excerpts (5.2 provides other rates for transaminase elevations and a jaundice case, but not this figure).
Symptoms of liver damage from Lipitor include fatigue.
No symptom list such as fatigue is provided in the provided label excerpts.
Symptoms of liver damage from Lipitor include loss of appetite.
No symptom list such as loss of appetite is provided in the provided label excerpts.
Symptoms of liver damage from Lipitor include nausea and vomiting.
No symptom list such as nausea/vomiting is provided in the provided label excerpts.
Symptoms of liver damage from Lipitor include abdominal pain (upper right side of the abdomen).
No symptom list such as upper right abdominal pain is provided in the provided label excerpts.
Symptoms of liver damage from Lipitor include dark urine.
No symptom list such as dark urine is provided in the provided label excerpts.
The text states that taking other medications, such as warfarin or amiodarone, may increase the risk of liver damage from Lipitor.
In the provided excerpts, the warfarin section (7.7) addresses prothrombin time impact; no label support is provided linking warfarin or amiodarone to increased liver damage risk.
The text states that if symptoms of liver damage occur while taking Lipitor, the medication should be stopped and medical attention sought immediately.
The provided label excerpt (5.2) recommends monitoring and actions based on persistent ALT/AST elevations (>3 times ULN), but does not provide the specific “stop and seek immediate medical attention if symptoms occur” instruction in the provided evidence.
The text states that a doctor may recommend alternative treatments for cholesterol if liver damage occurs from Lipitor.
No alternative-treatment recommendation is present in the provided label excerpts.
The text states that if liver damage is experienced from Lipitor, alternative cholesterol treatments may be recommended.
No alternative-treatment recommendation is present in the provided label excerpts.
The text states that older adults may be more sensitive to the effects of Lipitor and may be at a higher risk of liver damage.
The provided geriatric excerpt (8.5) discusses greater sensitivity of some older adults cannot be ruled out, and notes myopathy risk as a predisposing factor; it does not state higher risk of liver damage.
Contradictions
Low
AI Statement
The text states that liver damage occurs in about 1 in 100,000 people who take Lipitor.
Label Reference
5.2 Liver Dysfunction (provided label excerpts do not include this incidence figure)
Important Omissions
When describing safety risk, the label excerpts emphasize monitoring thresholds and actions (e.g., liver function tests timing; consider dose reduction/withdrawal if ALT or AST >3 times ULN persists). These specific label-based action thresholds were not reflected in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Unsupported/unquantified liver injury incidence, an unsupported symptom list, and incorrect or unverifiable interaction and emergency-action language could mislead risk perception and management relative to the label’s monitoring and ALT/AST threshold guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are not supported by the provided FDA-approved label excerpts, including an unlabeled incidence estimate, a detailed symptom inventory, and medication-interaction/emergency stop instructions not described in the cited label sections.
Suggested Improvement
Remove or revise unsupported incidence and symptom claims; align liver safety statements strictly to the provided label language (transaminase elevations rates, jaundice mention, contraindication definition for active liver disease, and monitoring/dose reduction/withdrawal guidance based on ALT/AST >3x ULN persistence). Ensure drug-interaction statements match the label’s described interaction outcomes.